Similar articles for PMID: 11864920

Year	Number of Results
1954	1
1959	1
1976	1
1980	2
1984	1
1990	1
1991	1
1993	4
1994	5
1995	6
1996	2
1997	9
1998	6
1999	6
2000	6
2001	13
2002	13
2003	11
2004	7
2005	2
2006	4
2007	5
2008	5
2009	4
2010	9
2011	8
2012	8
2013	3
2014	2
2015	2
2016	2
2017	1
2019	2
2021	3
2022	2
2023	2
2024	0

1

Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy.

Merlini PA, Repetto A, Lombardi A, Vetrano A, Fetiveau R, Cavallini C, Sappè D, Salvioni A, Canziani R, Savonitto S, Mannucci PM, Ardissino D. Merlini PA, et al. Circulation. 2002 Feb 26;105(8):928-32. doi: 10.1161/hc0802.104456. Circulation. 2002. PMID: 11864920 Clinical Trial.

2

Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation.

Mak KH. Mak KH. Circulation. 2002 Sep 24;106(13):e57. doi: 10.1161/01.cir.0000031832.54054.a1. Circulation. 2002. PMID: 12270876 No abstract available.

3

Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.

James SK, Siegbahn A, Armstrong P, Barnathan E, Califf R, Simoons ML, Wallentin L. James SK, et al. Am Heart J. 2004 Feb;147(2):267-74. doi: 10.1016/j.ahj.2003.09.014. Am Heart J. 2004. PMID: 14760324 Clinical Trial.

4

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.

Simoons ML; GUSTO IV-ACS Investigators. Simoons ML, et al. Lancet. 2001 Jun 16;357(9272):1915-24. doi: 10.1016/s0140-6736(00)05060-1. Lancet. 2001. PMID: 11425411 Clinical Trial.

5

Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.

Salvioni A, Casilli F, Assanelli E, Grazi M, Marenzi G, Guazzi MD. Salvioni A, et al. Thromb Haemost. 2001 Oct;86(4):991-4. Thromb Haemost. 2001. PMID: 11686357 Clinical Trial.

6

Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.

Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol E, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators. Ottervanger JP, et al. Circulation. 2003 Jan 28;107(3):437-42. doi: 10.1161/01.cir.0000046487.06811.5e. Circulation. 2003. PMID: 12551868 Clinical Trial.

7

Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.

Mak KH, Lee LH, Wong A, Chan C, Koh TH, Lau KW, Lim YL. Mak KH, et al. Am J Cardiol. 2002 Apr 15;89(8):930-6. doi: 10.1016/s0002-9149(02)02241-5. Am J Cardiol. 2002. PMID: 11950430 Clinical Trial.

8

Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.

Lenderink T, Boersma E, Ruzyllo W, Widimsky P, Ohman EM, Armstrong PW, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators. Lenderink T, et al. Am Heart J. 2004 May;147(5):865-73. doi: 10.1016/j.ahj.2003.11.009. Am Heart J. 2004. PMID: 15131544 Clinical Trial.

9

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Kastrati A, et al. JAMA. 2006 Apr 5;295(13):1531-8. doi: 10.1001/jama.295.13.joc60034. Epub 2006 Mar 13. JAMA. 2006. PMID: 16533938 Clinical Trial.

10

Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.

Merlini PA, Repetto A, Andreoli AM, Ricci S, Lombardi A, Finardi A, Dipasquale G, Lamponi M, Mannucci PM, Ardissino D. Merlini PA, et al. Am J Cardiol. 2004 Jan 15;93(2):195-8. doi: 10.1016/j.amjcard.2003.09.036. Am J Cardiol. 2004. PMID: 14715345 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

154 results

Results by year